Active substance
Sulfacetamide
- SFDA 9
- US FDA 33
- US price lines 6
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| APISULFA 20% EYE DROPS | 20 % | Eye drops · Ocular use | 1 Dropper Container | SAR 2.45 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Withdrawn by MAH · Not Marketed |
| CETAMIDE 10% OPTH.OINT. | 10 % | Eye ointment · Ocular use | 1 Tube | SAR 8.45 | Generic · Prescription | ALCON LABORATORIES | Withdrawn by MAH · Not Marketed |
| COLIRCUSI SULPHACETAMIDE 10% | 10 % | Eye drops · Ocular use | 1 Dropper Container | SAR 4.75 | Generic · Prescription | ALCON CUSI | Withdrawn by MAH · Not Marketed |
| COLIRCUSI SULPHACETAMIDE 20% | 20 % | Eye drops · Ocular use | 1 Dropper Container | SAR 3.05 | Generic · Prescription | ALCON CUSI | Withdrawn by MAH · Not Marketed |
| ISOPTO CETAMIDE 10% EYE DROPS | 10 % | Eye drops · Ocular use | 1 Dropper Container | SAR 15.85 | NCE · Prescription | ALCON COUVREUR | Withdrawn by MAH · Not Marketed |
| ISOPTOCETAMIDE 15% EYE DROPS | 15 % | Eye drops · Ocular use | 1 Dropper Container | SAR 8.40 | Generic · Prescription | ALCON COUVREUR | Withdrawn by MAH · Not Marketed |
| RIACETAMIDE | 10 % | Eye drops · Ocular use | 1 Dropper Container | SAR 6.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIACETAMIDE | 10 % | eye gel · Ocular use | 1 Bottle | SAR 10.45 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIACETAMIDE -20 | 20 % | Eye drops · Ocular use | 1 Dropper Container | SAR 6.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SULFACETAMIDE SODIUM | 10% | solution/drops · ophthalmic | CHARTWELL RX | Prescription | 18 Oct 1988 |
| SULFACETAMIDE SODIUM | 10% | solution/drops · ophthalmic | BAUSCH AND LOMB | Prescription | 28 Dec 1994 |
| KLARON | 10% | lotion · topical | BAUSCH | Prescription | 23 Dec 1996 |
| SULFACETAMIDE SODIUM | 10% | lotion · topical | FOUGERA PHARMS | Prescription | 17 Nov 2006 |
| SULFACETAMIDE SODIUM | 10% | lotion · topical | PADAGIS US | Prescription | 23 Mar 2009 |
| SODIUM SULAMYD | 10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 30% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | SCHERING | Discontinued | 21 Jul 1946 |
| SODIUM SULAMYD | 10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ointment · ophthalmic | SCHERING | Discontinued | 21 Jul 1946 |
| SULFACEL-15 | 15% | solution/drops · ophthalmic | OPTOPICS | Discontinued | 29 Sep 1970 |
| ISOPTO CETAMIDE | 15% | solution/drops · ophthalmic | ALCON | Discontinued | 5 May 1971 |
| BLEPH-10 | 10% | solution/drops · ophthalmic | ALLERGAN | Discontinued | 25 May 1971 |
| BLEPH-30 | 30% | solution/drops · ophthalmic | ALLERGAN | Discontinued | 25 May 1971 |
| SULFACETAMIDE SODIUM | 10% | ointment · ophthalmic | PADAGIS US | Discontinued | 22 Dec 1971 |
| OCUSULF-10 | 10% | solution/drops · ophthalmic | MIZA PHARMS USA | Discontinued | 24 Aug 1972 |
| OCUSULF-30 | 30% | solution/drops · ophthalmic | MIZA PHARMS USA | Discontinued | 24 Aug 1972 |
| CETAMIDE | 10% | ointment · ophthalmic | ALCON | Discontinued | 27 Sep 1972 |
| SODIUM SULFACETAMIDE | 10% | solution/drops · ophthalmic | SOLA BARNES HIND | Discontinued | 1 Nov 1974 |
| SODIUM SULFACETAMIDE | 30% | solution/drops · ophthalmic | SOLA BARNES HIND | Discontinued | 1 Nov 1974 |
| SODIUM SULFACETAMIDE | 10% | solution/drops · ophthalmic | SOLA BARNES HIND | Discontinued | 22 Nov 1974 |
| SODIUM SULFACETAMIDE | 30% | solution/drops · ophthalmic | SOLA BARNES HIND | Discontinued | 10 Dec 1974 |
| BLEPH-10 | 10% | ointment · ophthalmic | ALLERGAN | Discontinued | 7 Jan 1975 |
| SULFAIR 10 | 10% | ointment · ophthalmic | PHARMAFAIR | Discontinued | 22 Dec 1982 |
| SULTEN-10 | 10% | solution/drops · ophthalmic | BAUSCH AND LOMB | Discontinued | 3 Feb 1983 |
| SULFACETAMIDE SODIUM | 30% | solution/drops · ophthalmic | ALCON PHARMS LTD | Discontinued | 5 May 1987 |
| SULF-15 | 15% | solution/drops · ophthalmic | NOVARTIS | Discontinued | 31 Oct 1995 |
| SULFACETAMIDE SODIUM | 10% | solution/drops · ophthalmic | PHARMOBEDIENT | Discontinued | 25 May 1999 |
8 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SODIUM SULFACETAMIDE 10% WASH | $0.23985 | per ML | 19 Aug 2026 |
| US NADAC | SODIUM SULFACETAMIDE 10% WASH | $0.11351 | per GM | 23 Sep 2026 |
| US NADAC | SODIUM SULFACETAMIDE 10% WASH | $0.10577 | per GM | 22 Apr 2026 |
| US NADAC | SODIUM SULFACETAMIDE 10% WASH | $0.0849 | per GM | 23 Sep 2026 |
| US NADAC | SULFACETAMIDE 10% EYE DROPS | $1.96185 | per ML | 23 Sep 2026 |
| US NADAC | SULFACETAMIDE SOD 10% TOP SUSP | $0.51502 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Jul 2017 BLEPHAMIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Combinations containing Sulfacetamide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.